Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 59Colorectal Neoplasms 45Rectal Neoplasms 35Stomach Neoplasms 27Pancreatic Neoplasms 27Neoplasm Metastasis 24Neoplasms 19Colonic Neoplasms 18Triple Negative Breast Neoplasms 7Esophageal Neoplasms 6Adenocarcinoma 6Liver Neoplasms 5Brain Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Head and Neck Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma, Ovarian Epithelial 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Unknown Primary 2Melanoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma 2Breast Neoplasms, Male 2

Interventions

Nivolumab 2tislelizumab 1avelumab 1Taxes 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Ipilimumab 1Fluorouracil 1Carboplatin 1Capecitabine 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Turcot syndrome × Capecitabine × Clear all
NCT03050814 2021-12-20

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
30 enrolled 15 charts
Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡